Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/25460
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-03-30T13:26:21Z-
dc.date.available2022-03-30T13:26:21Z-
dc.date.issued2012-08-
dc.identifier.citationCivaner, M. (2012). "Sale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remain". Health Policy, 106(3), 225-232.en_US
dc.identifier.issn0168-8510-
dc.identifier.issn1872-6054-
dc.identifier.urihttps://doi.org/10.1016/j.healthpol.2012.05.006-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168851012001509-
dc.identifier.urihttp://hdl.handle.net/11452/25460-
dc.descriptionBu çalışma, Ankara Üniversitesi Sağlık Bilimleri Enstitüsünde Berna Arda'nın danışmanlığında Murat Civaner tarafından yazılan "Türkiye'de ilaç şirketlerinin kullandıkları pazarlama yöntemleri ve hekimlerin bu konudaki değerlendirmelerinin etik açıdan sorgulanması" adlı doktora tezine dayanılarak hazırlanmıştır.tr_TR
dc.description.abstractObjective: This study aimed to examine the types of sales strategies used by pharmaceutical companies in a "pharmerging" market and to gain insight into the ways of avoiding the negative effects of these strategies. Method: In-depth interviews were conducted with 22 physicians and company employees in the six largest cities of Turkey. The interviews were analyzed using content analysis. Results: Various sales strategies, both legal and illegal, are universally applied. These methods target prescribers, patients, pharmacists, and society in general. Different types of companies, organizations, professionals, and science and ethical principles are used as means. Companies intervene immediately to prevent developments that may decrease sales, and exploit the educational and infrastructural needs. In contrast, physicians are overconfident about the effects of marketing and insufficiently educated on how to cope with the strategies and the drugs on the market, which make them vulnerable. Under these conditions, along with worldwide competition and economic volatility, policies that aim to set frameworks for pharmaceutical relationships have failed. Conclusion: Interventions are crucial, including instituting a national drug policy, minimizing the exposure to marketing, and addressing the educational and infrastructural needs of the prescribers. Without these interventions, gaps will continue to be exploited by companies for their own advantage, and the problems related to marketing will persist.en_US
dc.language.isoenen_US
dc.publisherElsevier Irelanden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHealth care sciences & servicesen_US
dc.subjectMarketingen_US
dc.subjectDrug industryen_US
dc.subjectPhysiciansen_US
dc.subjectMedical ethicsen_US
dc.subjectProfessionalismen_US
dc.subjectDrug companiesen_US
dc.subjectMedical journalsen_US
dc.subjectIndustryen_US
dc.subjectDoctorsen_US
dc.subjectPhysiciansen_US
dc.subjectSponsorshipen_US
dc.subjectAssociationen_US
dc.subjectGuidelinesen_US
dc.subjectEducationen_US
dc.subjectAuthorsen_US
dc.subject.meshDrug industryen_US
dc.subject.meshEthics, medicalen_US
dc.subject.meshHumansen_US
dc.subject.meshMarketingen_US
dc.subject.meshQualitative researchen_US
dc.subject.meshTurkeyen_US
dc.titleSale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remainen_US
dc.typeArticleen_US
dc.identifier.wos000306885900002tr_TR
dc.identifier.scopus2-s2.0-84863780162tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıp Etiği Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-5376-3499tr_TR
dc.identifier.startpage225tr_TR
dc.identifier.endpage232tr_TR
dc.identifier.volume106tr_TR
dc.identifier.issue3tr_TR
dc.relation.journalHealth Policyen_US
dc.contributor.buuauthorCivaner, Murat-
dc.contributor.researcheridS-4188-2019tr_TR
dc.identifier.pubmed22682762tr_TR
dc.subject.wosHealth care sciences & servicesen_US
dc.subject.wosHealth policy & servicesen_US
dc.indexed.wosSCIEen_US
dc.indexed.wosSSCIen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ2 (Health policy & services)en_US
dc.wos.quartileQ3 (Health care sciences & services)en_US
dc.contributor.scopusid24075622600tr_TR
dc.subject.scopusConflict of Interests; Honorarium; Consulting Feesen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeDrug industryen_US
dc.subject.emtreeDrug marketingen_US
dc.subject.emtreeEmployeeen_US
dc.subject.emtreeHealth care policyen_US
dc.subject.emtreeHealth economicsen_US
dc.subject.emtreeInterviewen_US
dc.subject.emtreePharmacisten_US
dc.subject.emtreePhysicianen_US
dc.subject.emtreeQualitative researchen_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.